A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC 725085, ALLIANCE IND 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Vitespen (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- 06 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Nov 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jul 2017.
- 26 Jan 2016 Planned number of patients changed from 222 to 165, according to ClinicalTrials.gov record.